Vals Mari-Anne, Yakoreva Maria, Kahre Tiina, Mee Pille, Muru Kai, Joost Kairit, Teek Rita, Soellner Lukas, Eggermann Thomas, Õunap Katrin
1 Department of Genetics, United Laboratories, Tartu University Hospital , Tartu, Estonia .
2 Department of Pediatrics, University of Tartu , Tartu, Estonia .
Genet Test Mol Biomarkers. 2015 Dec;19(12):684-91. doi: 10.1089/gtmb.2015.0163. Epub 2015 Oct 27.
To study the frequency of methylation abnormalities among Estonian patients selected according to published clinical diagnostic scoring systems for Silver-Russell syndrome (SRS) and Beckwith-Wiedemann syndrome (BWS).
Forty-eight patients with clinical suspicion of SRS (n = 20) or BWS (n = 28) were included in the study group, to whom methylation-specific multiplex ligation-dependant probe amplification analysis of 11p15 region was made. In addition, to patients with minimal diagnostic score for either SRS or BWS, multilocus methylation-specific single nucleotide primer extension assay was performed.
Five (38%) SRS patients with positive clinical scoring had abnormal methylation pattern at chromosome 11p15, whereas in the BWS group, only one patient was diagnosed with imprinting control region 2 (ICR2) hypomethylation (8%). An unexpected hypomethylation of the PLAGL1 (6q24) and IGF2R (6q25) genes in the patient with the highest BWS scoring was found.
Compared to BWS, diagnostic criteria used for selecting SRS patients gave us a similar detection rate of 11p15 imprinting disorders as seen in other studies. A more careful selection of patients with possible BWS should be considered to improve the detection of molecularly confirmed cases. Genome-wide multilocus methylation tests could be used in routine clinical practice as it increases the detection rates of imprinting disorders.
根据已发表的Silver-Russell综合征(SRS)和Beckwith-Wiedemann综合征(BWS)临床诊断评分系统,研究爱沙尼亚患者中甲基化异常的频率。
研究组纳入48例临床疑似SRS(n = 20)或BWS(n = 28)的患者,对其进行11p15区域的甲基化特异性多重连接依赖性探针扩增分析。此外,对SRS或BWS诊断评分最低的患者进行多位点甲基化特异性单核苷酸引物延伸分析。
5例(38%)临床评分阳性的SRS患者在11号染色体p15区域存在甲基化模式异常,而在BWS组中,仅有1例患者被诊断为印记控制区2(ICR2)低甲基化(8%)。在BWS评分最高的患者中发现了PLAGL1(6q24)和IGF2R(6q25)基因意外的低甲基化。
与BWS相比,用于选择SRS患者的诊断标准使我们对11p15印记障碍的检测率与其他研究相似。应考虑更谨慎地选择可能患有BWS的患者,以提高分子确诊病例的检出率。全基因组多位点甲基化检测可用于常规临床实践,因为它能提高印记障碍的检出率。